Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activi...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Patel, Samir N., McGeer, Allison, Melano, Roberto, Tyrrell, Gregory J., Green, Karen, Pillai, Dylan R., Low, Donald E.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2011
Предметы:
Epidemiology and Surveillance
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147653/
https://ncbi.nlm.nih.gov/pubmed/21628545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00237-11
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы